Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists
- 1 November 2003
- journal article
- review article
- Published by Springer Nature in Current Urology Reports
- Vol. 4 (6) , 457-465
Abstract
The prominence of phosphodiesterase-5 (PDE-5) inhibitors in the treatment of male erectile dysfunction and other diseases related to vascular dysfunction mandates a comprehensive understanding of the properties and effects of these compounds. Three potent and selective PDE-5 inhibitors (sildenafil, tadalafil, and vardenafil) have been approved for clinical use. The clinical efficacy and safety profiles of these medications are related to their molecular mode of action, the selectivity for PDE-5, and the pharmacokinetic properties (absorption, bioavailability, time to onset of action, distribution, metabolism, and elimination). These PDE-5 inhibitors share some common properties with regard to mechanisms of action and selectivities for PDE-5. They also have distinctive characteristics that may impact their clinical use. This article focuses on the basic biochemistry of cyclic guanosine monophosphate signaling and the pharmacokinetic parameters that describe characteristics of drug action of these PDE-5 inhibitors in facilitating smooth muscle relaxation, leading to improved penile erectile response or causing side effects.Keywords
This publication has 47 references indexed in Scilit:
- [3H]Sildenafil Binding to Phosphodiesterase-5 Is Specific, Kinetically Heterogeneous, and Stimulated by cGMPMolecular Pharmacology, 2003
- Direct activation of PDE5 by cGMPJournal of Cell Biology, 2003
- Use of sildenafil citrate in Raynaud's phenomenon: Comment on the article by Thompson et alArthritis & Rheumatism, 2003
- Signaling through NO and cGMP‐dependent protein kinasesAnnals of Medicine, 2003
- Sildenafil citrate does not affect cardiac contractility in human or dog heartCurrent Medical Research and Opinion, 2003
- Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neuronsJournal of Neuroscience Research, 2002
- The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trialInternational Journal Of Impotence Research, 2001
- EFFECTS OF SILDENAFIL ON THE RELAXATION OF HUMAN CORPUS CAVERNOSUM TISSUE IN VITRO AND ON THE ACTIVITIES OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ISOZYMESJournal of Urology, 1998
- Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscleBiochemical and Biophysical Research Communications, 1990
- Activation of purified guanylate cyclase by nitric oxide requires heme comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lungBiochimica et Biophysica Acta (BBA) - General Subjects, 1982